CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.
  
  OVERVIEW OF ACTIVITY
  Recent developments have led to an explosion in lung cancer genetic and biologic knowledge, but the integration of anti-PD-1/PD-L1 checkpoint inhibitors into treatment and the evolution of targeted therapy have complicated decision-making for clinicians caring for patients with metastatic non-small cell lung cancer (NSCLC). To bridge the gap between research and patient care, this video presentation by Alexander E Drilon uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists and other healthcare providers involved in the treatment of lung cancer with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Evaluate existing guideline recommendations regarding the indications and optimal testing platform for mutational analysis for patients with metastatic NSCLC, and use this information to implement a comprehensive approach to genomic assessment.
  • Use mutation status, clinical characteristics and tumor histology to appropriately prioritize front-line and subsequent treatment approaches for patients with metastatic NSCLC.
  • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC, and discern how novel EGFR tyrosine kinase inhibitors can be optimally administered to patients with progressive EGFR mutation-positive disease.
  • Communicate the efficacy and safety of approved and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
  • Recall existing and emerging research information demonstrating the efficacy and safety of anti-PD-1/PD-L1 antibodies for patients with squamous and nonsquamous metastatic NSCLC, and use this information to guide treatment planning.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in NSCLC, and counsel appropriately selected patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Presenting Faculty Member
  
  Alexander E Drilon, MD
  Clinical Director
  Developmental Therapeutics Clinic
  Assistant Attending Physician
  Thoracic Oncology Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GlaxoSmithKline, Ignyta Inc, Loxo Oncology Inc, Pfizer Inc, Roche Laboratories Inc, TP Therapeutics Inc.
  
  Project Steering Committee Members
  
  Julie R Brahmer, MD
  Director, Thoracic Oncology Program
  Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
  Associate Professor of Oncology
  Sidney Kimmel Comprehensive Cancer Center
  Johns Hopkins School of Medicine
  Baltimore, Maryland
  
  Advisory Committee: Bristol-Myers Squibb Company, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, MedImmune Inc, Merck.
  
  Paul A Bunn Jr, MD
  Distinguished Professor and James Dudley Chair in Cancer Research
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Advisory Committee: Genentech BioOncology, Lilly, Merck, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Pfizer Inc.
  
  D Ross Camidge, MD, PhD
  Professor of Medicine/Oncology
  Joyce Zeff Chair in Lung Cancer Research
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Advisory Committee: Mersana Therapeutics; Contracted Research and Other Remunerated Activities: Roche Laboratories Inc, Takeda Oncology.
  
  David E Gerber, MD
  Associate Professor
  Division of Hematology-Oncology
  Associate Director for Clinical Research
  Co-Leader, Experimental Therapeutics Program
  Co-Director, Lung Disease Oriented Team
  Harold C Simmons Comprehensive Cancer Center
  University of Texas Southwestern Medical Center
  Dallas, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Guardant Health Inc, MSPharma, Peregrine Pharmaceuticals Inc, Samsung Bioepis, Synta Pharmaceuticals Corp; Contracted Research: ArQule Inc, BerGenBio ASA, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, ImmunoGen Inc, Karyopharm Therapeutics, Peregrine Pharmaceuticals Inc.
  
  Sarah B Goldberg, MD, MPH
  Assistant Professor of Medicine
  Medical Oncology
  Yale Cancer Center
  New Haven, Connecticut
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Lilly; Contracted Research: AstraZeneca Pharmaceuticals LP.
  
  Roy S Herbst, MD, PhD
  Ensign Professor of Medicine (Oncology)
  Professor of Pharmacology
  Chief of Medical Oncology
  Director, Thoracic Oncology Research Program
  Associate Director for Translational Research
  Yale Comprehensive Cancer Center
  Yale School of Medicine
  Smilow Cancer Hospital
  New Haven, Connecticut
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Lilly, Merck, Pfizer Inc; Contracted Research: Genentech BioOncology, Merck.
  
  John V Heymach, MD, PhD
  Professor and Chair
  Thoracic/Head and Neck Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Lilly, Merck, Novartis, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc.
  
  Leora Horn, MD, MSc
  Associate Professor of Medicine
  Clinical Director, Thoracic Oncology Research Program
  Assistant Vice Chairman for Faculty Development
  Vanderbilt University Medical Center
  Nashville, Tennessee
  
  Advisory Committee: AbbVie Inc, Genentech BioOncology, Merck; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Lilly, Xcovery; Paid Travel: Boehringer Ingelheim Pharmaceuticals Inc.
  
  Edward S Kim, MD
  Professor and Chair
  Department of Solid Tumor Oncology and Investigational Therapeutics
  Levine Cancer Institute
  Carolinas HealthCare System
  Charlotte, North Carolina
  
  Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly.
  
  Mark G Kris, MD
  William and Joy Ruane Chair in Thoracic Oncology
  Attending Physician, Thoracic Oncology Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreement: AstraZeneca Pharmaceuticals LP.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Vice Chair, Radiation Therapy Oncology Group
  Philadelphia, Pennsylvania
  
  Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Ariad Pharmaceuticals Inc, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc.
  
  Renato G Martins, MD, MPH
  Stephen H Petersdorf Endowed Chair in Cancer Care
  Associate Medical Director
  Solid Tumor Adult Oncology
  Seattle Cancer Care Alliance
  Professor
  University of Washington
  Seattle, Washington
  
  Contracted Research: Eisai Inc, Lilly, Merck.
  
  Joel W Neal, MD, PhD
  Assistant Professor of Medicine
  Division of Oncology
  Stanford Cancer Institute
  Stanford University
  Palo Alto, California
  
  Advisory Committee and Consulting Agreements: Ariad Pharmaceuticals Inc, ARMO BioSciences, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Lilly, Nektar, Physician Resource Management Inc; Contracted Research: Ariad Pharmaceuticals Inc, ArQule Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck, Nektar, Novartis, Roche Laboratories Inc.
  
  Paul K Paik, MD
  Assistant Attending Physician
  Clinical Director, Thoracic Oncology Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Lilly.
  
  Jyoti D Patel, MD
  Professor of Medicine
  The University of Chicago
  Chicago, Illinois
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Takeda Oncology.
  
  Nathan A Pennell, MD, PhD
  Associate Professor, Hematology and Medical Oncology
  Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
  Director, Cleveland Clinic Lung Cancer Medical Oncology Program
  Cleveland, Ohio
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Regeneron Pharmaceuticals Inc; Consulting Agreement: Lilly; Contracted Research: Merck.
  
  Suresh S Ramalingam, MD
  Professor of Hematology and Medical Oncology
  Assistant Dean for Cancer Research
  Emory University School of Medicine
  Deputy Director, Winship Cancer Institute
  Atlanta, Georgia
  
  Advisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Takeda Oncology.
  
  Lecia V Sequist, MD, MPH
  Associate Professor of Medicine
  Harvard Medical School
  Center for Thoracic Cancers
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc, Novartis.
  
  Mark A Socinski, MD
  Executive Medical Director
  Member, Thoracic Oncology Program
  Florida Hospital Cancer Institute
  Orlando, Florida
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Takeda Oncology.
  
  David R Spigel, MD
  Program Director, Lung Cancer Research
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Novartis, Pfizer Inc, Roche Laboratories Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.
  
  Thomas E Stinchcombe, MD
  Thoracic Oncology Program
  Duke University Medical Center
  Durham, North Carolina
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Regeneron Pharmaceuticals Inc.
  
  Anne S Tsao, MD
  Professor
  Director, Mesothelioma Program
  Director, Thoracic Chemo-Radiation Program
  Department of Thoracic/Head and Neck Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Lilly, Merck, Novartis, Roche Laboratories Inc; Consulting Agreements: Lilly, Novartis, Roche Laboratories Inc; Contracted Research: Ariad Pharmaceuticals Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Epizyme Inc, Merck, Polaris Group, Seattle Genetics, Takeda Oncology.
  
  Everett E Vokes, MD
  John E Ultmann Professor
  Chairman, Department of Medicine
  Physician-in-Chief, University of Chicago Medicine and Biological Sciences
  Chicago, Illinois
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, EMD Serono Inc; Consulting Agreements: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Genentech BioOncology, Lilly, Merck, Regeneron Pharmaceuticals Inc, Takeda Oncology, VentiRx Pharmaceuticals Inc.
  
  Heather Wakelee, MD
  Professor of Medicine
  Division of Oncology
  Stanford University School of Medicine
  Stanford Cancer Institute
  Stanford, California
  
  Consulting Agreements: ACEA Biosciences Inc, Genentech BioOncology, Helsinn Group, Peregrine Pharmaceuticals Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, Lilly, MedImmune Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Xcovery; Honoraria: ACEA Biosciences Inc, Helsinn Group, Peregrine Pharmaceuticals Inc.
  
  PROJECT CHAIR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Merck.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: March 2018
  Expiration date: March 2019